Table 5

Application of the rule out strategies to women with PE

PatientHaemoptysisClinical signs DVTPE most likely diagnosisGeneva scoreD-dimerThrombo-prophylaxisAnticoagulant (time before D-dimer)YEARS/D-dimer strategyGeneva/D-dimer strategy
1NoYesNo12708NoDalteparin
7500 IU, 14 hours
PEPE
2NoNoNo51469NoDalteparin
6000 IU, 2 hour
PEPE
3NoNoYes54802YesTinzaparin
19 000 IU, 16 hours
PEPE
4NoNoNo6261YesNo*No PENo PE
5NoNoNo0823NoTinzaparin
175 u/kg, 0 hour
PEPE
6NoNoNo51444NoDalteparin
7500 IU, 4.5 hours
PEPE
7NoYesYes92696NoDalteparin
7500 IU, 7 hours
PEPE
8NoNoNo5662NoDalteparin
10 000 IU, 7 hours
No PEPE
9NoYesNo15194YesDalteparin
12 500 IU, 2 hours
No PEPE
10YesNoNo5265YesEnoxaparin
80 mg, 6.5 hours
No PENo PE
11NoNoYes5263NoNoNo PENo PE
12NoNoYes54329NoTinzaparin
18 000 IU, 13.5 hour
PEPE
  • *Recorded as receiving no anticoagulation before blood sampling, but also recorded as commencing tinazaparin 15 000 IU daily for thromboprophylaxis 3 months prior to presentation.

  • DVT, deep vein thrombosis ; PE, pulmonary embolism.